InMed seeks to protect patent for cannabinoid glaucoma formulation

InMed Pharmaceuticals has filed a Patent Cooperation Treaty application for INM-085, a cannabinoid-based therapy for the topical treatment of glaucoma, the company announced in a press release.
The filing would include protection of InMed’s technology in 150 countries, including the United States, and has a priority date from May 8, 2018, the release said.
“With the filing of this patent application, we are continuing the process of pursuing commercial protection for our novel technologies, in this case until May 2038. This is particularly important to the company as we undertake

Full Story →